Pharma Generics Theme  ·  Active Funds Only

Pharma Generics — Mutual Fund Holdings Tracker

Track how many active mutual funds hold pharma generics stocks in India. Monthly data shows where institutional conviction across Sun Pharma, Cipla, Dr Reddys, Lupin, Torrent, Aurobindo, Alkem, Zydus, Mankind and others is rising or falling.

📅 Updated Oct 2026  ·  Index funds and ETFs excluded

45
Stocks Tracked
421
Active Funds Holding (Oct 2026)
₹164,811 Cr
Active MF Investment (Oct 2026)
Jul 2026 — fund count in Jul 2026 (base month) · Aug % / Sep % / Oct % — month-on-month change in funds holding the stock · Oct 2026 Funds — funds holding as of Oct 2026 · Overall % — total change Jul 2026 to Oct 2026. Blue = growing interest, Red = exiting · AUM (₹ Cr) — total market value held by active funds in Oct 2026 Active equity funds only  ·  Index funds and ETFs excluded
# Stock Name Jul Aug % Sep % Oct % Oct 2026 Funds Overall % AUM (₹ Cr)
1 Sun Pharmaceutical Industries LimitedPharmaceuticals & Biotechnology 215 -7.9%+0.5% -4.5% 190 -11.6% 23,945
2 Torrent Pharmaceuticals LimitedPharmaceuticals & Biotechnology 141 +1.4%-1.4% -3.5% 136 -3.5% 9,633
3 Aurobindo Pharma LimitedPharmaceuticals & Biotechnology 88 -3.4%-9.4% +28.6% 99 +12.5% 12,338
4 Mankind Pharma LimitedPharmaceuticals & Biotechnology 103 -7.8%+3.2% -3.1% 95 -7.8% 9,418
5 Cipla LimitedPharmaceuticals & Biotechnology 95 -1.1%-2.1% +1.1% 93 -2.1% 15,062
6 Dr. Reddy's Laboratories LimitedPharmaceuticals & Biotechnology 58 +8.6%+27% +7.5% 86 +48.3% 7,405
7 IPCA Laboratories LimitedPharmaceuticals & Biotechnology 68 -7.4%+6.3% +9% 73 +7.4% 14,052
8 Ajanta Pharma LimitedPharmaceuticals & Biotechnology 83 -6%-3.8% -4% 72 -13.3% 6,495
9 Biocon LimitedPharmaceuticals & Biotechnology 78 -11.5%+1.4% +2.9% 72 -7.7% 8,635
10 Lupin LimitedPharmaceuticals & Biotechnology 87 -19.5%+7.1% -4% 72 -17.2% 9,930
11 Zydus Lifesciences LimitedPharmaceuticals & Biotechnology 35 +37.1%+2.1% +44.9% 71 +102.9% 7,756
12 Glenmark Pharmaceuticals LimitedPharmaceuticals & Biotechnology 62 -1.6%-1.6% +1.7% 61 -1.6% 7,139
13 Abbott India LimitedPharmaceuticals & Biotechnology 59 -1.7%+10.3% -12.5% 56 -5.1% 3,079
14 Alkem Laboratories LimitedPharmaceuticals & Biotechnology 62 -14.5%+3.8% -3.6% 53 -14.5% 7,456
15 GlaxoSmithKline Pharmaceuticals LimitedPharmaceuticals & Biotechnology 39 +7.7%-2.4% +12.2% 46 +17.9% 2,325
16 Corona Remedies LimitedPharmaceuticals & Biotechnology 23 -8.7%+42.9% +3.3% 31 +34.8% 1,998
17 Eris Lifesciences LimitedPharmaceuticals & Biotechnology 32 -12.5%+3.6% -10.3% 26 -18.8% 2,167
18 Natco Pharma LimitedPharmaceuticals & Biotechnology 13 +7.7%+7.1% +66.7% 25 +92.3% 716
19 Pfizer LimitedPharmaceuticals & Biotechnology 30 +6.7%-25% 0% 24 -20% 1,818
20 Wockhardt LimitedPharmaceuticals & Biotechnology 24 -33.3%+50% 0% 24 0% 1,402
21 Emcure Pharmaceuticals LimitedPharmaceuticals & Biotechnology 21 +4.8%0% 0% 22 +4.8% 2,374
22 SANOFI CONSUMER HEALTHCAREPharmaceuticals & Biotechnology 25 -4%-4.2% -4.3% 22 -12% 901
23 Sudeep Pharma LimitedPharmaceuticals & Biotechnology 20 +10%-9.1% +10% 22 +10% 785
24 Orchid Pharma LimitedPharmaceuticals & Biotechnology 22 -4.5%-4.8% +5% 21 -4.5% 763
25 AstraZeneca Pharma India LimitedPharmaceuticals & Biotechnology 20 0%-5% +5.3% 20 0% 1,001
26 Granules India LimitedPharmaceuticals & Biotechnology 9 +77.8%-6.3% +13.3% 17 +88.9% 531
27 Senores Pharmaceuticals LtdPharmaceuticals & Biotechnology 15 0%+6.7% +6.3% 17 +13.3% 385
28 Alembic Pharmaceuticals LimitedPharmaceuticals & Biotechnology 16 -12.5%+14.3% -6.3% 15 -6.3% 1,072
29 Marksans Pharma LimitedPharmaceuticals & Biotechnology 11 0%+9.1% +8.3% 13 +18.2% 467
30 Sanofi India LimitedPharmaceuticals & Biotechnology 15 -13.3%-15.4% +9.1% 12 -20% 636
31 FDC LimitedPharmaceuticals & Biotechnology 7 0%0% 0% 7 0% 314
32 Gufic Biosciences Ltd.Pharmaceuticals & Biotechnology 5 +20%+16.7% 0% 7 +40% 120
33 Caplin Point Laboratories LimitedPharmaceuticals & Biotechnology 5 -20%+50% 0% 6 +20% 227
34 Strides Pharma Science LimitedPharmaceuticals & Biotechnology 7 -14.3%-66.7% +200% 6 -14.3% 1,048
35 Alivus Life SciencesPharmaceuticals & Biotechnology 7 0%-57.1% +66.7% 5 -28.6% 668
36 Indoco Remedies LtdPharmaceuticals & Biotechnology 6 -16.7%-20% +25% 5 -16.7% 275
37 Aarti Pharmalabs LimitedPharmaceuticals & Biotechnology 2 0%0% +100% 4 +100% 39
38 Novartis India LimitedPharmaceuticals & Biotechnology 4 -25%+33.3% 0% 4 0% 24
39 Amrutanjan Health Care Ltd.Pharmaceuticals & Biotechnology 3 0%0% 0% 3 0% 36
40 Unichem Laboratories Ltd.Pharmaceuticals & Biotechnology 2 0%0% 0% 2 0% 295
41 Zota Health Care LimitedPharmaceuticals & Biotechnology 1 -100%— +100% 2 +100% 15
42 Amanta Healthcare LimitedPharmaceuticals & Biotechnology 1 0%0% 0% 1 0% 33
43 Bajaj Healthcare LimitedPharmaceuticals & Biotechnology 1 0%0% 0% 1 0% 17
44 Morepen Laboratories LimitedPharmaceuticals & Biotechnology — —— — 1 — 11
45 ZIM LABORATORIES LTDPharmaceuticals & Biotechnology 1 0%0% 0% 1 0% 9
46 Bliss GVS Pharma LimitedPharmaceuticals & Biotechnology 1 -100%— — — -100% —
Share:

What are pharma generics stocks and which ones do mutual funds track in India?

Pharma generics stocks include Indian companies that manufacture and sell branded generic formulations in domestic and export markets. The segment covers large-cap leaders like Sun Pharmaceutical, Cipla, Dr Reddys Laboratories, Lupin, Torrent Pharmaceuticals and Aurobindo Pharma, mid-cap names like Alkem Laboratories, Zydus Lifesciences, Mankind Pharma, IPCA Laboratories and Ajanta Pharma, and challenger brands like Glenmark, JB Chemicals, Emcure and Eris Lifesciences. India is the pharmacy of the world — the largest supplier of generic medicines globally by volume — and this theme captures the companies that drive that position.

Rising fund counts over four months signal growing institutional conviction in the pharma generics theme. Cross-reference individual fund portfolios on our top stocks page or explore full holdings via the funds directory.

Why are mutual funds buying pharma generics stocks in India right now?

India pharma generics companies are benefiting from multiple tailwinds simultaneously. US generics pricing has stabilised after years of erosion, improving export margins for companies like Sun Pharma, Lupin and Dr Reddys. Domestic branded generics are growing steadily as healthcare spending rises and insurance coverage expands. Chronic disease categories — cardiovascular, diabetes, oncology — are growing fast and favour companies with strong chronic portfolios like Torrent and Alkem. New product launches, biosimilars, and complex generics are creating incremental growth opportunities. Fund managers hold generics as core defensive positions with export diversification.

For context on SEBI disclosure requirements, refer to AMFI India. For regulatory guidelines, visit SEBI India. Explore broader holding trends using our market cap categories page.

What does the AUM column show on pharma generics theme pages?

The AUM column shows the total market value of holdings in that stock across all active equity mutual funds in the latest month, expressed in crores of rupees. A high AUM alongside a rising fund count signals strong and growing conviction, while a falling fund count with still-high AUM may indicate remaining funds are holding larger positions even as others exit. This data is updated automatically each month as new portfolio disclosures are uploaded.

To explore individual fund portfolios and see which specific funds hold each pharma generics stock, visit the funds directory or click any stock name in the table above. Use the SIP calculator to plan investments in funds with high pharma sector exposure. For a broader market view, see our AAUM data page.

Disclaimer: RightAdvise is a data and research platform. Fund holding data is sourced from monthly portfolio disclosures published by mutual funds as required by SEBI. AUM figures are calculated from reported market values and may differ from official AMC disclosures. This page is for informational purposes only and does not constitute investment advice. Past holding trends do not guarantee future performance. Please consult a SEBI-registered investment adviser before making any investment decisions.